Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19

Anticoagulant therapy is a cornerstone treatment for coronavirus disease 2019 (COVID-19) due to the high rates of thromboembolic complications associated with this disease. We hypothesized that chronic antithrombotic therapy could play a protective role in patients hospitalized for COVID-19. Retrosp...

Descripción completa

Detalles Bibliográficos
Autores: Corrochano, M, Acosta-Isaac, R, Mojal, S, Miqueleiz, S, Rodriguez, D, Quijada-Manuitt, MA, Fraga, E, Castillo-Ocana, M, Amaro-Hosey, K, Albiol, N, Soria, JM, Antonijoan, RM, Souto, JC
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p4609
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4609
Access Level:acceso abierto
Palabra clave:Anticoagulants
Antiplatelet drugs
Covid-19
Intensive care
Mortality
id ES_9338dba902e809d9b9a975f683bc4e43
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p4609
network_acronym_str ES
network_name_str España
repository_id_str
spelling Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19Corrochano, MAcosta-Isaac, RMojal, SMiqueleiz, SRodriguez, DQuijada-Manuitt, MAFraga, ECastillo-Ocana, MAmaro-Hosey, KAlbiol, NSoria, JMAntonijoan, RMSouto, JCAnticoagulantsAntiplatelet drugsCovid-19Intensive careMortalityAnticoagulant therapy is a cornerstone treatment for coronavirus disease 2019 (COVID-19) due to the high rates of thromboembolic complications associated with this disease. We hypothesized that chronic antithrombotic therapy could play a protective role in patients hospitalized for COVID-19. Retrospective, observational study of all patients admitted to our hospital for >= 24 h from March 1 to May 31, 2020 with SARS-CoV-2. The objective was to evaluate clinical outcomes and mortality in COVID-19 patients receiving chronic anticoagulation (AC) or antiplatelet therapy (AP) prior to hospital admission. A total of 1612 patients were evaluated. The mean (standard deviation; SD) age was 66.5 (17.1) years. Patients were divided into three groups according to the use of antithrombotic therapy prior to admission (AP, AC, or no-antithrombotic treatment). At admission, 9.6% of the patients were taking anticoagulants and 19.1% antiplatelet therapy. The overall mortality rate was 19.3%. On the multivariate analysis there were no significant differences in mortality between the antithrombotic groups (AC or AP) and the no-antithrombotic group (control group). Patients on AC had lower ICU admission rates than the control group (OR: 0.41, 95% CI, 0.18-0.93). Anticoagulation therapy prior to hospitalization for COVID-19 was associated with lower ICU admission rates. However, there were no significant differences in mortality between the patients receiving chronic antithrombotic therapy and patients not taking antithrombotic medications. These findings suggest that chronic anticoagulation therapy at the time of COVID-19 infection may reduce disease severity and thus the need for ICU admission.SPRINGER2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4609JOURNAL OF THROMBOSIS AND THROMBOLYSISISSN: 09295305ISSNe: 1573742Xreponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p46092026-06-14T12:41:47Z
dc.title.none.fl_str_mv Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19
title Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19
spellingShingle Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19
Corrochano, M
Anticoagulants
Antiplatelet drugs
Covid-19
Intensive care
Mortality
title_short Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19
title_full Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19
title_fullStr Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19
title_full_unstemmed Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19
title_sort Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19
dc.creator.none.fl_str_mv Corrochano, M
Acosta-Isaac, R
Mojal, S
Miqueleiz, S
Rodriguez, D
Quijada-Manuitt, MA
Fraga, E
Castillo-Ocana, M
Amaro-Hosey, K
Albiol, N
Soria, JM
Antonijoan, RM
Souto, JC
author Corrochano, M
author_facet Corrochano, M
Acosta-Isaac, R
Mojal, S
Miqueleiz, S
Rodriguez, D
Quijada-Manuitt, MA
Fraga, E
Castillo-Ocana, M
Amaro-Hosey, K
Albiol, N
Soria, JM
Antonijoan, RM
Souto, JC
author_role author
author2 Acosta-Isaac, R
Mojal, S
Miqueleiz, S
Rodriguez, D
Quijada-Manuitt, MA
Fraga, E
Castillo-Ocana, M
Amaro-Hosey, K
Albiol, N
Soria, JM
Antonijoan, RM
Souto, JC
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Anticoagulants
Antiplatelet drugs
Covid-19
Intensive care
Mortality
topic Anticoagulants
Antiplatelet drugs
Covid-19
Intensive care
Mortality
description Anticoagulant therapy is a cornerstone treatment for coronavirus disease 2019 (COVID-19) due to the high rates of thromboembolic complications associated with this disease. We hypothesized that chronic antithrombotic therapy could play a protective role in patients hospitalized for COVID-19. Retrospective, observational study of all patients admitted to our hospital for >= 24 h from March 1 to May 31, 2020 with SARS-CoV-2. The objective was to evaluate clinical outcomes and mortality in COVID-19 patients receiving chronic anticoagulation (AC) or antiplatelet therapy (AP) prior to hospital admission. A total of 1612 patients were evaluated. The mean (standard deviation; SD) age was 66.5 (17.1) years. Patients were divided into three groups according to the use of antithrombotic therapy prior to admission (AP, AC, or no-antithrombotic treatment). At admission, 9.6% of the patients were taking anticoagulants and 19.1% antiplatelet therapy. The overall mortality rate was 19.3%. On the multivariate analysis there were no significant differences in mortality between the antithrombotic groups (AC or AP) and the no-antithrombotic group (control group). Patients on AC had lower ICU admission rates than the control group (OR: 0.41, 95% CI, 0.18-0.93). Anticoagulation therapy prior to hospitalization for COVID-19 was associated with lower ICU admission rates. However, there were no significant differences in mortality between the patients receiving chronic antithrombotic therapy and patients not taking antithrombotic medications. These findings suggest that chronic anticoagulation therapy at the time of COVID-19 infection may reduce disease severity and thus the need for ICU admission.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4609
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4609
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER
publisher.none.fl_str_mv SPRINGER
dc.source.none.fl_str_mv JOURNAL OF THROMBOSIS AND THROMBOLYSIS
ISSN: 09295305
ISSNe: 1573742X
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413564031172608
score 15,812455

Similares en LA Referencia